RE 104
Alternative Names: RE-104Latest Information Update: 29 Jul 2024
At a glance
- Originator Reunion Neuroscience
- Class Antidepressants
- Mechanism of Action Serotonin 5-HT2A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Postnatal depression
Most Recent Events
- 29 Jul 2024 Pharmacokinetics, pharmacodynamics and adverse events data from a phase I trial in Postnatal depression released by Reunion Neuroscience (prior to July 2024) (Reunion Neuroscience Pipeline, July 2024)
- 14 Jun 2024 Phase-II clinical trials in Postnatal depression in USA (SC) (NCT06342310)
- 03 Apr 2024 Reunion Neuroscience plans a phase II RECONNECT trial for Postpartum depression (SC, Injection) (NCT06342310)